(Total Views: 151)
Posted On: 04/09/2024 8:30:47 AM
Post# of 61

$GALT News Article - Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis https://marketwirenews.com/news-releases/gale...73648.html


My Twitter: WhyteStocks